Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel
Overview
- Phase
- Phase 4
- Intervention
- Prasugrel
- Conditions
- Coronary Artery Disease
- Sponsor
- University of Sao Paulo
- Enrollment
- 87
- Locations
- 1
- Primary Endpoint
- To compare platelet inhibition between the two groups (ticagrelor and prasugrel)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease
Detailed Description
This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) . Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and \> 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points
Investigators
Jose Carlos Nicolau
Director Coronary Care Unit
University of Sao Paulo
Eligibility Criteria
Inclusion Criteria
- •between 18 and 75 years old
- •were on aspirin
- •without P2Y12 inhibitor at baseline
- •\> 1 year after documented acute coronary syndrome
Exclusion Criteria
- •use of oral anticoagulation or P2Y12 at baseline
- •Weight \< 60kg
- •History of tia or stroke
- •Any coagulation disorders
- •Refuse to sign the written consent
Arms & Interventions
Prasugrel group
Prasugrel (60mg loading dose, followed by 10 mg QD for 15 days) + Ticagrelor placebo (Placebo loading dose followed by two pills a day)
Intervention: Prasugrel
Prasugrel group
Prasugrel (60mg loading dose, followed by 10 mg QD for 15 days) + Ticagrelor placebo (Placebo loading dose followed by two pills a day)
Intervention: Ticagrelor
Ticagrelor group
Ticagrelor (180mg loading dose, followed by 90 mg BID) + Prasugrel placebo (Placebo loading dose followed by one pill a day)
Intervention: Prasugrel
Ticagrelor group
Ticagrelor (180mg loading dose, followed by 90 mg BID) + Prasugrel placebo (Placebo loading dose followed by one pill a day)
Intervention: Ticagrelor
Outcomes
Primary Outcomes
To compare platelet inhibition between the two groups (ticagrelor and prasugrel)
Time Frame: 15 days
Platelet aggregation was compared with the Multiplate ADP® assay at baseline and after 15 days on study medication
To compare adenosine levels between the two groups (ticagrelor and prasugrel)
Time Frame: 15 days
Adenosine plasma levels were measured at baseline and after 15 days with high performance liquid chromatography at the same time points